News

Australia 2025 Flu Peak and Europe’s Outlook

The Australia flu season 2025 peaked unusually early, between June and July, well before the historical average. Its rapid growth, strong community transmission, and elevated clinical severity make it one of the most significant flu waves in recent years. According to the Australian Respiratory Surveillance Report, influenza, Respiratory Syncytial Virus (RSV) and SARS-CoV-2 are circulating simultaneously at high levels, creating a “tripledemic” scenario that is driving hospitalizations and straining healthcare services during the Australian influenza season 2025.

For public health authorities and professionals across Europe, monitoring these trends from the Australian flu season is essential to understand how the upcoming autumn–winter respiratory season may unfold. This is especially relevant within the broader context of respiratory infections and integrated surveillance systems.

This article analyzes the latest surveillance data from Australia to assess the likely timing, severity, and dominant viral strains of the European flu season 2025–2026. Australia’s experience acts as an early indicator, supporting European countries in preparing for a potentially high-burden season and mitigating the expected rise in cases, hospitalizations, and mortality.

Australia, Europe’s early warning system

Due to its opposite seasonal cycle, similar circulating strains, vaccine formulations, demographic vulnerabilities, and strong national influenza surveillance infrastructure, Australia serves as a sentinel for the Northern Hemisphere’s upcoming flu season. The Australia flu season often anticipates what Europe and North America will face during their fall and winter months. Notably, even the WHO Global Influenza Program relies on Southern Hemisphere data to help determine the composition of the Northern Hemisphere vaccine.

This year, activity began rising sharply in May, and according to the Australian Respiratory Surveillance Report, influenza-like infection consultation rates in general practice sentinel networks have surpassed the five-year average, signaling high community transmission. These patterns have historically preceded intense flu seasons in Europe.

The good news is that genomic surveillance confirms the 2025 Southern Hemisphere strains are antigenically comparable to circulating ones, suggesting favorable influenza vaccine. However, case numbers remain high, pointing to suboptimal vaccination coverage as a key driver of transmission during the Australia flu season.

For European health systems, this means that even with an optimally matched vaccine, low vaccination rates will still lead to hospitalizations and ICU admissions during the European flu season 2025–2026.

Australia’s flu season 2025 in numbers

The current rate of respiratory infections is the highest since 2019, surpassing levels seen in 2023 and 2024. This resurgence indicates a post-pandemic return to pre-COVID-19 circulation patterns, with increased population vulnerability due to waning immunity and reduced non-pharmaceutical interventions.

The 2025 flu season in Australia has been characterized by both volume and speed:

● Between May and June 2025, monthly influenza cases more than doubled in most Australian regions.

● Over 150,000 laboratory-confirmed influenza cases have been reported since the beginning of 2025, according to the Royal Australian College of General Practitioners.

● Hospitalizations for severe acute respiratory infections reached 7,641, including 3,081 due to influenza—the highest among all respiratory pathogens.

● Influenza was the second most common pathogen causing ICU admissions, behind only rhinovirus/enterovirus.

The demographic impact of this year’s season is also clear: children aged 0-9 experienced the highest infection rates, while hospitalizations and severe outcomes remain concentrated among adults over 65. This age difference highlights the dual burden of influenza, high transmission in younger populations and high severity in older adults.

Although influenza cases declined during July 14–27, RSV remains elevated and COVID-19 continues contributing to ICU admissions, confirming sustained flu, RSV, and COVID-19 co-circulation.

Flu, RSV, and COVID-19: the 2025 “tripledemic”

The Australia flu season exemplifies the post-pandemic “respiratory tripledemic,” characterized by concurrent circulation of influenza, RSV, and SARS-CoV-2. Data from the Short Period Incidence Study of Severe Acute Respiratory Infection shows that 4.4% of patients had co-detections of multiple pathogens, increasing clinical complexity and ICU admissions influenza RSV COVID.

Additional pathogens such as human metapneumovirus, rhinovirus, and Bordetella pertussis have also contributed to the disease burden, especially in pediatric ICU cases. These agents, although less common, can prolong illness and mimic influenza, leading to diagnostic delays.

These findings highlight the need for integrated surveillance systems capable of tracking multiple pathogens simultaneously and providing real-time information for public health responses.

Europe’s winter forecast

Based on patterns observed during the Australia flu season, epidemiologists forecast a high-burden, early, and potentially severe European flu season 2025–2026.

● Early and Intense Season: The early peak in Australia often correlates with earlier and more intense seasons in the Northern Hemisphere. The European flu season is expected to begin from late October to mid-November 2025, with a peak between late December 2025 and January 2026. The season is projected to end around March to April 2026, with possible residual circulation into May.

● Co-Circulation of Pathogens: Similar flu RSV COVID-19 co-circulation is expected.

● High Burden: Based on Australia’s experience and assuming current vaccination rates, Europe could see an estimated 125-215 million total respiratory cases during the 2025-2026 season, affecting 15-25% of the population.

The dominant strains are expected to be similar to those in Australia: influenza A H1N1 and H3N2, and B/Victoria. However, the severity of the season will depend on other factors, particularly vaccination coverage and public awareness, which could pose a significant risk for uncontrolled spread.

Age, vaccination, and health gaps: who is most at risk?

The connection between low vaccination rates and disease burden observed during the Australia flu season is clear. Only 29.5% of Australians had received a flu shot by late July 2025. Of note, 90% of hospitalized flu patients are unvaccinated.

Adults over 65 account for 50% of influenza hospitalizations, while children, though less likely to be hospitalized, play a key role in transmission. School-based outbreaks can spark community-wide spread, making pediatric vaccination a key part of herd immunity.

Immunocompromised patients and those with comorbidities face higher risk of severe outcomes, yet are often excluded from routine surveillance. Mortality data from the Australian Bureau of Statistics show that deaths linked to influenza, RSV, and COVID-19 remain elevated compared to pre-pandemic levels. Among ICU admissions, in-hospital mortality rates are 9.4% for influenza, 16.6% for COVID-19, and 6.0% for RSV.

These figures highlight the ongoing lethality of respiratory pathogens, especially among vulnerable populations. Clearly, disparities in healthcare access worsen outcomes. Rural and underserved communities often face limited access to vaccines, testing, and care, leading to delayed treatment and higher severity.

In Europe, similar trends are observed. Flu vaccination coverage among older adults remains alarmingly low 57-60% in Italy and 10-25% in Eastern Europe, far below the WHO’s recommended 75% target for high-risk groups. The consequences are clear: increased hospitalizations, ICU admissions, and preventable deaths during the European flu season 2025–2026.

For this reason, European public health messaging must focus on active engagement, leveraging trusted community leaders, digital platforms, and workplace programs to boost vaccination rates.

Emerging threats & surveillance needs

In addition to seasonal influenza, new and re-emerging pathogens demand vigilance. Australia reported outbreaks of highly pathogenic avian influenza H7N8 in Victoria and is currently monitoring a few cases of H5N1.

While no human cases have been reported, respiratory symptoms in individuals exposed to poultry must be documented and thoroughly evaluated. These zoonotic threats serve as a reminder of what happened just five years ago with COVID-19 and emphasize the importance of a One Health approach, integrating human, animal, and environmental monitoring.

SARS-CoV-2 continues to evolve. For instance, the XFG sub-lineage, designated as a Variant Under Monitoring by WHO in June 2025, requires genomic tracking to assess immune escape and transmissibility. Updated COVID-19 boosters targeting this variant are expected to be available in Europe by fall 2025.

Regarding healthcare system needs, strengthening national influenza surveillance networks and reference laboratories is essential for quick data sharing, accurate burden assessment, and rapid response.

This includes validated sample collection systems, multiplex PCR platforms, next-generation sequencing (NGS), and automated sample processing tools. Incorporating these diagnostic solutions into laboratory workflows will improve efficiency and data quality.

Five ways Europe can prepare for the 2025–2026 season

Monitor Australia’s Surveillance Data: monitoring data from the Australia flu season in real-time will help assess strain dominance, clinical severity, and adjust forecasts.
Strengthen Integrated Surveillance: expand national and international systems to track flu, RSV, COVID-19, and emerging pathogens using standardized case definitions and data sharing protocols through platforms like the European Centre for Disease Prevention and Control (ECDC). This will be crucial for real-time monitoring and a coordinated response.
Promote Vaccination Campaigns: targeted, culturally sensitive campaigns can increase uptake among seniors, healthcare workers, and children. Prioritizing high-risk groups, expanding access points, and integrating vaccination into routine clinical workflows must also be considered.
Prepare Healthcare Systems: hospitals should anticipate increased admissions, especially in geriatric and pediatric units. Contingency plans for ICU capacity, staffing, and antiviral supply should be reviewed for the European flu season 2025–2026. Ensuring protective equipment and vaccinating healthcare workers may help mitigate transmission within healthcare facilities.
Support Labs and Diagnostics Providers: collaborate with laboratories to streamline testing workflows, validate platforms, and provide reliable collection and processing tools tailored to local needs.

Key Takeaways for Europe’s 2025–2026 Season

The Australia flu season 2025-2026 serves as a crucial early warning for Europe: winter 2025–2026 may be one of the most challenging in years. With an estimated 150–215 million cases across EMEA, proactive measures are vital.

The quick onset, high case numbers, and respiratory tripledemic conditions highlight the need for proactive public health actions and clinical preparedness. Enhanced surveillance, timely diagnostic testing, and strong healthcare system planning will be essential to reduce the impact of the European flu season 2025–2026.

By learning from the Australia flu season, Europe can strengthen its preparedness and better protect vulnerable populations during the upcoming winter months.

Bibliography

Join CoScience HUB

Create your CoScience HUB account now to access cutting-edge science and position yourself at the forefront of innovation.